- Home
- ROIV vs OKTA Comparison
ROIV vs OKTA Comparison
Compare ROIV & OKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | OKTA |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 15.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ROIV | OKTA |
|---|---|---|
| Price | $22.78 | $90.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 37 |
| Target Price | $24.31 | ★ $116.86 |
| AVG Volume (30 Days) | ★ 5.9M | 2.2M |
| Earning Date | 02-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.08 |
| Revenue | $20,329,000.00 | ★ $2,840,000,000.00 |
| Revenue This Year | N/A | $13.64 |
| Revenue Next Year | $741.42 | $9.10 |
| P/E Ratio | ★ N/A | $84.42 |
| Revenue Growth | N/A | ★ 12.12 |
| 52 Week Low | $8.73 | $75.05 |
| 52 Week High | $23.91 | $127.57 |
Technical Indicators
Market Signals| Indicator | ROIV | OKTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 52.68 |
| Support Level | $22.50 | $87.12 |
| Resistance Level | $23.20 | $97.45 |
| Average True Range (ATR) | 0.75 | 3.63 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 63.73 | 46.62 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.